Clinical Trials Browser

Phase 1 × MORAb-202 × Clear all

NCT03386942 2022-11-28

A Study of MORAb-202 (Herein Referred to as Farletuzumab Ecteribulin) in Participants With Solid Tumors

Phase 1 Completed

Pyogenic arthritis, pyoderma gangrenosum, and acne, Carcinoma, Non-Small-Cell Lung